Reported about 1 year ago
Hims & Hers Health, a telehealth provider, is capitalizing on the scarcity of obesity drugs by offering compounded forms of injections using active ingredients from popular drugs like Ozempic. While the market opportunity seems promising due to the high demand for weight-loss medications, uncertainties loom over the company's long-term strategy, especially considering the possibility of reduced demand once supply constraints ease. Compounded drugs are currently in high demand due to shortages, but potential legal risks and regulatory challenges could arise in the future.
Source: YAHOO